Solara Active Pharma Sciences Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Solara Active Pharma Sciences reported Q1 FY27 revenue of INR384 crores, up 20% year-on-year, with EBITDA of INR63.5 crores and PAT of INR16.3 crores, which management said were the highest EBITDA and PAT in 18 quarters. The base business grew 24% year-on-year while the commodity Ibuprofen business reported a negative 12% EBITDA margin amid raw material cost pressures linked to the West Asia crisis. Management also reported a reduction in net debt of roughly INR135 crores during the quarter, bringing net debt to approximately INR479 crores.
Solara reported Q4 FY26 revenue of Rs 392 crore, up 12% quarter-on-quarter, with EBITDA of Rs 61 crore, up 65% Q-o-Q, driven by the base business which operates at higher margins. The ibuprofen business continued to post negative EBITDA, and the Board has appointed bankers to evaluate strategic options for it, with a conclusion expected in H1 FY27. The company also reduced debt by roughly Rs 158 crore during FY26, aided by rights issue call money and operational cash flows.